Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20201855 | 0.91 | ENPP2 (0.67) | ENPP2HDAC6HDAC1HDAC4HDAC2 | |
| SCHEMBL16750310 | 0.86 | ENPP2 (0.79) | ENPP2HDAC6HDAC1HDAC4HDAC2 | |
| SCHEMBL18044833 | 0.85 | ENPP2 (0.72) | ENPP2HDAC6HDAC1HDAC4HDAC2 | |
| SCHEMBL16750302 | 0.85 | ENPP2 (0.74) | ENPP2HDAC6HDAC1HDAC4HDAC2 | |
| SCHEMBL18269181 | 0.84 | ENPP2 (0.72) | ENPP2HDAC6HDAC1HDAC4HDAC2 | |
| SCHEMBL16750219 | 0.82 | ENPP2 (0.77) | ENPP2HDAC6HDAC1HDAC4HDAC2 | |
| SCHEMBL16750211 | 0.82 | ENPP2 (0.82) | ENPP2HDAC6HDAC1HDAC4HDAC2 | |
| SCHEMBL16750182 | 0.81 | ENPP2 (0.81) | ENPP2HDAC6HDAC1HDAC4HDAC2 | |
| SCHEMBL16750178 | 0.81 | ENPP2 (1.00) | ENPP2HDAC6HDAC1HDAC4HDAC2 | |
| SCHEMBL16750306 | 0.81 | ENPP2 (1.00) | ENPP2HDAC6HDAC1HDAC4HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200215034-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | INSOLVENCY SERVICES GROUP, INC. | 2020-07-09 | — | — | US | disclosed |
| US-10632104-B2 | Autotaxin inhibitors and uses thereof | SABRE THERAPEUTICS LLC (US) | 2020-04-28 | — | — | US | disclosed |
| US-20180147185-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | PHARMAKEA, INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180147185-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | PHARMAKEA, INC. (US) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180147185-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | ENPP2, SERPINB1, RNASE1 | ENPP2 1/4885HDAC6 448/4885HDAC1 2293/4885 |
| US-10632104-B2 | Autotaxin inhibitors and uses thereof | ENPP2, SERPINB1, RNASE1 | ENPP2 1/4885HDAC6 448/4885HDAC1 2293/4885 |
| US-20200215034-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | ENPP2, SERPINB1, RNASE1 | ENPP2 1/4885HDAC6 448/4885HDAC1 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.